These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25005458)

  • 1. Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls.
    Zibar K; Ćuća JK; Blaslov K; Bulum T; Smirčić-Duvnjak L
    Ann Clin Biochem; 2015 Mar; 52(Pt 2):220-5. PubMed ID: 25005458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1.
    Blaslov K; Bulum T; Zibar K; Duvnjak L
    J Diabetes; 2015 May; 7(3):340-6. PubMed ID: 25042812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
    Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
    Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus.
    Hillman M; Eriksson L; Mared L; Helgesson K; Landin-Olsson M
    J Cyst Fibros; 2012 Mar; 11(2):144-9. PubMed ID: 22138561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery.
    Stadler M; Krššák M; Jankovic D; Göbl C; Winhofer Y; Pacini G; Bischof M; Haidinger M; Saemann M; Mühlbacher F; Korbonits M; Baumgartner-Parzer SM; Luger A; Prager R; Anderwald CH; Krebs M
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):208-13. PubMed ID: 23302039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
    Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous blood provides lower glucagon-like peptide-1 concentrations than arterialized blood in the postprandial but not the fasted state: Consequences of sampling methods.
    Chen YC; Edinburgh RM; Hengist A; Smith HA; Walhin JP; Betts JA; Thompson D; Gonzalez JT
    Exp Physiol; 2018 Sep; 103(9):1200-1205. PubMed ID: 29947441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin and glucagon levels in adult offspring exposed to maternal diabetes in pregnancy.
    Kelstrup L; Clausen TD; Mathiesen ER; Hansen T; Holst JJ; Damm P
    J Clin Endocrinol Metab; 2015 May; 100(5):1967-75. PubMed ID: 25781355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.
    Thivolet C; Marchand L; Chikh K
    Diabetologia; 2019 Apr; 62(4):593-597. PubMed ID: 30612138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues.
    Kamoi K; Shinozaki Y; Furukawa K; Sasaki H
    Endocr J; 2011; 58(10):905-11. PubMed ID: 21878743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.
    Vilsbøll T; Agersø H; Krarup T; Holst JJ
    J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
    Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.